Trial Profile

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NYX-458 (Primary)
Indications Dementia; Lewy body disease; Mild cognitive impairment; Parkinson's disease
Focus Adverse reactions; Therapeutic Use
Sponsors Aptinyx

Most Recent Events

27 Feb 2023 According to an Aptinyx media release, results do not support further development of NYX-458 by the company.
27 Feb 2023 Results presented in a Aptinyx media release.
25 Aug 2022 Status changed from recruiting to active, no longer recruiting, according to an Aptinyx media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com